From Medscape Diabetes & Endocrinology

Conference Coverage From The

American Diabetes Association (ADA) 80th Scientific Sessions

June 12 - 16, 2020; Chicago, IL - A Virtual Experience

June 12 - 16, 2020 Chicago, IL - A Virtual Experience

ADA 2020 SGLT2 Inhibitors Now 'Belong to Cardiologists and Nephrologists' Physicians of different specialties are still getting used to the idea that SGLT2 inhibitors aren't just for diabetes anymore.
Medscape Medical News, July 16, 2020
ADA 2020 DPPOS at 22 Years: 'Diabetes Prevention Is Possible' Long Term 'Even after 22 years, adults at a high risk for [type 2] diabetes have continued to benefit from metformin, or prior intensive lifestyle modification, in preventing or delaying' disease development.
Medscape Medical News, June 24, 2020
ADA 2020 VERTIS-CV: Late-Comer Ertugliflozin Shows HF Benefit Only in CVOT The findings are consistent with previous cardiovascular outcome trials of other SGLT2 inhibitors in type 2 diabetes, says an expert.
Medscape Medical News, June 18, 2020

American Diabetes Association is hosting a virtual session this year

Conference News

ADA 2020 SGLT2 Inhibitors Now 'Belong to Cardiologists and Nephrologists'
Medscape Medical News, July 16, 2020
ADA 2020 Endocrine Hospitalist-Led Service Improves Diabetes Care
Medscape Medical News, July 10, 2020
ADA 2020 Weight Loss Not Fiber Intake Tied to Better A1c in Diabetes
Medscape Medical News, July 8, 2020
ADA 2020 Better Pregnancy Spacing Would Aid Those With Gestational Diabetes
Medscape Medical News, July 2, 2020
ADA 2020 Cognitive Deficits Complex in Youths With Type 2 Diabetes
Medscape Medical News, July 2, 2020
ADA 2020 How Many Hormones Make an Ideal 'Artificial Pancreas?'
Medscape Medical News, July 1, 2020
ADA 2020 Contrave Boosts Weight Loss in Diabetes Patients on Incretins
Medscape Medical News, June 30, 2020
ADA 2020 Novel Program Cuts Weight Retention After Gestational Diabetes
Medscape Medical News, June 30, 2020
ADA 2020 Liraglutide Plus Exercise Helps Maintain Weight Loss: S-LITE
Medscape Medical News, June 29, 2020
ADA 2020 Diabetes-Related Amputations on the Rise in Older Adults
Medscape Medical News, June 26, 2020
ADA 2020 Lifestyle Intervention in Prediabetes Not Just About Weight Loss
Medscape Medical News, June 26, 2020
ADA 2020 Dapagliflozin's Renal Protection Extends to 'Fast Decline' of eGFR
Medscape Medical News, June 25, 2020
ADA 2020 Type 1 Diabetes Prevention Moves Toward Reality
Medscape Medical News, June 25, 2020
ADA 2020 Frequent Hypoglycemic Episodes Raise Cardiac Event Risk
Medscape Medical News, June 25, 2020
ADA 2020 DPPOS at 22 Years: 'Diabetes Prevention Is Possible' Long Term
Medscape Medical News, June 24, 2020
ADA 2020 BEST: Bexagliflozin CV Outcomes Trial Meets Objectives
Medscape Medical News, June 24, 2020

ADA 2020 Diabetes Control in US Youth Has Worsened Over Time
Medscape Medical News, June 22, 2020
ADA 2020 VERTIS-CV: Late-Comer Ertugliflozin Shows HF Benefit Only in CVOT
Medscape Medical News, June 18, 2020
ADA 2020 Gestational Diabetes Cut With Plant-Based Diet Before Pregnancy
Medscape Medical News, June 18, 2020
ADA 2020 Lipid-Lowering Bempedoic Acid Does Not Hasten or Worsen Diabetes
Medscape Medical News, June 17, 2020
ADA 2020 Calcium Scoring Pinpoints Stenoses in Asymptomatic Diabetes
Medscape Medical News, June 17, 2020
ADA 2020 DAPA-HF: Dapagliflozin Slows T2D Onset in Heart Failure Patients
Medscape Medical News, June 16, 2020
ADA 2020 CGM Use Benefits Youth, Older Adults With Type 1 Diabetes
Medscape Medical News, June 16, 2020
ADA 2020 Half of Young Adults With Diabetes Have Diastolic Dysfunction
Medscape Medical News, June 15, 2020
ADA 2020 High-Frequency Spinal Cord Stimulation Eases Diabetic Neuropathy Pain
Medscape Medical News, June 15, 2020
ADA 2020 Early Data on Once-Weekly Insulin; Will it Transform Treatment?
Medscape Medical News, June 15, 2020
ADA 2020 Those Most in Need Least Likely to Get Newer Diabetes Medications
Medscape Medical News, June 14, 2020
ADA 2020 EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes
Medscape Medical News, June 14, 2020
ADA 2020 SGLT2 Inhibitors vs GLP-1 Agonists for Diabetes in Real-World Study
Medscape Medical News, June 14, 2020
ADA 2020 FreeStyle Libre Glucose Monitor Reduces Hospitalizations in Diabetes
Medscape Medical News, June 14, 2020
ADA 2020 Automated Insulin Delivery System 'Getting Better and Better'
Medscape Medical News, June 13, 2020
ADA 2020 ADA Scientific Sessions Will Forge Ahead Virtually, Intact
Medscape Medical News, June 8, 2020

Medscape Diabetes© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Highlights From ADA 2020
Mary de Groot, PhD
'Stop Boring Patients': Tips for Engaging Diabetes Education
William H. Polonsky, PhD, CDE; Mark Harmel, MPH
CGM in Type 2 Diabetes: Invaluable or Too Expensive?
Akshay B. Jain, MD
The Future of Health Insurance for Patients With Diabetes
Robert E. Ratner, MD; Mark Harmel, MPH
CGM Use in T1D: Don't Count Older Patients Out
Richard Pratley, MD; Mark Harmel, MPH
VERTIS-CV Results 'Disappoint,' Raise More Questions
Harpreet S. Bajaj, MD, MPH
Irl Hirsch Reviews ADA Highlights With Anne Peters
Anne L. Peters, MD; Irl B. Hirsch, MD; Mark Harmel, MPH
Insulin Can't Solve Everything: Adjunctive Therapies in T1D
Jeremy Pettus, MD; Mark Harmel, MPH
When to Refer Patients for Diabetes Education: New Guidance
Margaret A. Powers, PhD, RD, CDCES;
Mark Harmel, MPH
Female Sexual Dysfunction: If We Don't Ask, We Won't Know
Alice Cheng, MD; Mark Harmel, MPH
Metabolic Disease: Is It the Fat, Sugar, or Processed Food?
Caroline M. Apovian, MD

Popular News from ADA 2019

'Alarming' Complications in 20-Year-Olds With Type 2 Diabetes I think we need to recognize that...in these younger kids we probably need even more aggressive management than many adults with type 2 diabetes,' says the lead author of the TODAY-2 study.
Medscape Medical News, Jun 09, 2019
Game Changer: Antibody First to Delay Type 1 Diabetes Onset in TrialNet Teplizumab, an investigational anti-CD3 monoclonal antibody, delayed the onset of type 1 diabetes for 2 years in patients in the TrialNet study. Experts urge caution but admit result is "terrific."
Medscape Medical News, Jun 10, 2019
Once-Weekly Dulaglutide Benefit in REWIND, Longest CVOT to Date Full results of REWIND show dulaglutide significantly reduces CV events in patients with type 2 diabetes who primarily have CVD risk factors, rather than CVD itself. The major effect seems to be on stroke.
Medscape Medical News, Jun 10, 2019
CREDENCE 'Knocks Your Socks Off'; New Analysis Reported at ADA Latest analysis of CREDENCE with SGLT2 inhibitor canagliflozin shows the agent has a cardio- and renal-protective effect in both primary and secondary CV prevention populations.
Medscape Medical News, Jun 17, 2019

Previous Coverage

ADA 2019